Sign in

ALKEM on National Stock Exchange of India

Alkem Laboratories

Indian pharmaceutical company

Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals, Alkem manufactures and markets pharmaceutical generics, formulations and nutraceuticals across India and global markets.2 It was founded by Samprada Singh.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1973Founded1

Compare with another stock.

  • TickerALKEM on National Stock Exchange of India1
  • Industrypharmaceutical industry1
  • HeadquartersMumbai1
  • Websitewww.alkemlabs.com
  • Legal formPublic Limited Company3
  • LEI335800GCAE5WIF4PSG693
  • StatusActive3
  • LEI statusIssued and current3
  • Registered addressALKEM HOUSE, 400013 Mumbai, India3
  • Registered withMinistry of Corporate Affairs, L00305MH1973PLC1742013

See how the biggest companies compare on our leaderboards

Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals, Alkem manufactures and markets pharmaceutical generics, formulations and nutraceuticals across India and global markets.2

Corporate structure

Alkem Laboratories sits at the top of its group. 9 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Alkem Laboratories Mumbai, India
    • ASCEND LABORATORIES SPA Subsidiary · 100% · Santiago, Chile
    • ASCEND LABORATORIES, LLC Subsidiary · 100% · Parsippany, New Jersey, United States
    • S&B PHARMA LLC Subsidiary · 100% · Azusa, California, United States
    • THE PHARMA NETWORK, LLC Subsidiary · 100% · Parsippany, New Jersey, United States
    • Товарищество с ограниченной ответственностью "The Pharmа Network" Subsidiary · 100% · Almaty, Kazakhstan
    • ENZENE BIOSCIENCES LIMITED Subsidiary · 99.84% · Pune, India
    • ADROIT BIOMED LIMITED Subsidiary · Mumbai, India
    • INDCHEMIE HEALTH SPECIALITIES PRIVATE LIMITED Subsidiary · Mumbai, India

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0). Each entity in the chart links to its source.

The story

Founded by Samprada Singh in 1973.1

Samprada Singh was the founder and chairman emeritus of the company; he had a B.Com degree from Patna University. His brother, Basudeo Narayan Singh, was also the co-founder of the company.

Alkem set up its research and development facility for ANDA development at Taloja in 2003. In 2006 anti-infective drug Taxim of Alkem became the first anti-infective drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India. In 2014 Clavam another drug from Alkem crossed 2,000 million mark in terms of domestic sales in India.

In 2007 the company filed its first ANDA for drug Amlodipine which was approved in 2009. Alkem has developed a portfolio of 705 branded generic drugs, with 13 of the brands featured among the top 300 brands in India for the fiscal year 2015 and a portfolio of 705 brands in India in the six months ended 30 September 2015. Alkem have 21 manufacturing facilities, 19 in India and 2 in US. 5 of the facilities are US FDA, TGA, UK MHRA approved.

Samprada Singh (1925–2019) died on 27 July 2019 at the age of 94 after a brief illness in Mumbai. In 2018, he was the 46th richest person in India.

From Wikipedia’s article on Alkem Laboratories, shared under CC BY-SA 4.0.4

Leadership

Who has led Alkem Laboratories, and when. Pick a name to see everywhere that person has worked.

Products and brands

  • medication

Listed on Wikidata.1

Subsidiaries and ownership

Owners

From Wikidata.1

Acquisitions

Alkem has 21 manufacturing facilities: 19 in India and 2 in the US. These 2 facilities in the US were acquired in 2012 and 2013 respectively. In 2014, Alkem acquired the "Clindac-A" brand in India from Galderma S.A. In 2015, Alkem acquired a formulation manufacturing facility in the US.

From Wikipedia’s article on Alkem Laboratories, shared under CC BY-SA 4.0.4

Timeline

  1. 1973Founded Founded1

Calendar

Drug trials and FDA: recently

  1. Jul 18, 2024Phase 3 trial completed Phase 3 trial of ENZ215 and Prolia in Postmenopausal Osteoporosis, run by Enzene Biosciences Ltd.: primary completion Jul 18, 2024, results posted Feb 10, 2026 (ClinicalTrials.gov NCT05405725).5

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5